Skip to main content
Main navigation
Home
About pCPA
Who We Are
Governance
FAQs
Negotiations
Recent Updates
Forms and Publications
Brand Name Drugs
Negotiations Status
Negotiation Process
Generic Drugs
Biologics/Biosimilars
Contact Us
EN
FR
Keytruda (pembrolizumab)
pCPA File Number:
21138
Negotiation Status:
Concluded with an LOI
Indication(s):
Melanoma adjuvant therapy
Sponsor/Manufacturer:
Merck Canada Inc.
CADTH Project Number:
pCODR 10168
pCPA Engagement Letter Issued:
2019-09-13
Negotiation Process Concluded:
2020-04-15